Bayer’s Supreme Court Gamble: A Parkinson’s Breakthrough Emerges From the Roundup Shadow

Bayer stock drops 4.6% as U.S. Supreme Court hears glyphosate case; 80% of Roundup claims at stake. Meanwhile, AskBio achieves key gene therapy milestone.

The German pharmaceutical and life sciences group is navigating one of the most bifurcated moments in its recent history. On one side, a landmark legal battle over glyphosate liability reaches the highest court in the United States, threatening to reshape the company’s financial future. On the other, its gene therapy pipeline has quietly delivered a critical manufacturing milestone that could redefine its long-term scientific credibility.

Investors, however, are not yet buying the optimism. Shares in Bayer closed at €36.62 on Tuesday, shedding 4.59% in a single session, pushing the year-to-date performance into negative territory. The stock now trades at €37.25, roughly 7% lower than a week ago, as the market digests the implications of the Supreme Court hearing in the Durnell case.

The Legal Crossroads: 80% of Claims Hanging in the Balance

At the heart of the oral arguments before the U.S. Supreme Court is a fundamental question of federal versus state authority. Bayer, leaning on the Environmental Protection Agency’s classification of glyphosate as safe, argues that specific cancer warning labels mandated by individual states are preempted by federal law. Plaintiffs, by contrast, point to stricter state-level statutes that they say should take precedence.

The justices appeared divided during the hearing. Justice Kavanaugh signaled openness to uniform federal standards, while Chief Justice Roberts emphasized the prerogatives of individual states. The outcome is binary in its potential impact: a ruling in Bayer’s favor would affect approximately 80% of the outstanding Roundup claims, dramatically reducing the company’s legal overhang.

A parallel deadline adds urgency. Plaintiffs have until June 4, 2026, to join an existing multibillion-dollar settlement framework. The final Supreme Court verdict is expected at the end of June 2026, creating a tight window for both sides to assess their options.

Analysts Hold the Line Despite Market Jitters

Major investment banks have maintained a cautiously constructive stance on the stock following the hearing. JPMorgan reiterates its “Overweight” rating with a €50 price target, while Barclays keeps its “Overweight” call at €48, noting that the justices’ questioning suggested a potential path forward. UBS confirms its “Buy” rating with a €52 target, arguing that the court covered all relevant arguments comprehensively.

The technical picture offers some solace. The share price remains above its 200-day moving average of €34.46, a level that has historically provided support. Still, the broader sentiment is tempered by the March sell-off that knocked the stock from a two-year high near €49.50, triggered by disappointment over the 2026 earnings guidance.

A Quiet Breakthrough in Parkinson’s Gene Therapy

While the legal drama dominates headlines, Bayer’s subsidiary AskBio has achieved a milestone that could prove equally consequential. In April, the company completed an IND amendment submission to the FDA for its Parkinson’s gene therapy candidate, Ametefgene Parvec (AB-1005). The regulatory green light allows the Phase II REGENERATE-PD study to source material from Viralgen’s commercial-scale manufacturing facility.

For gene therapies, the transition from clinical-grade to commercially scalable production is notoriously difficult—a bottleneck that has derailed promising candidates across the industry. That AskBio has cleared this hurdle strengthens the credibility of Bayer’s pipeline at a time when the company needs every narrative advantage it can muster.

Barclays sees 2026 as a trough year for Bayer’s pharma division, with mid-single-digit growth expected to resume from 2027 onward. Thirteen analysts currently rate the stock a buy, with an average price target of €47.63.

The Broader Picture: Pipeline Progress Meets Execution Risk

Bayer’s dual narrative—a legal sword of Damocles alongside genuine scientific progress—mirrors a wider tension in the pharmaceutical sector. Large caps like Bayer and BioNTech have the diversified pipelines and cash reserves to absorb setbacks, but the market is increasingly unforgiving of execution missteps.

The next catalyst on the calendar is Bayer’s quarterly report, which will provide fresh data on pharma revenues and the trajectory of legal costs. For now, the stock sits in a holding pattern, caught between the promise of a Supreme Court resolution and the reality of a 4.6% single-day drop. The final verdict, when it comes, will determine whether this is a turning point or just another chapter in a long-running saga.